Identification of Antimycobacterial Natural Products from a Library of Marine Invertebrate Extracts.
Kojo Sekyi AcquahDenzil R BeukesRonnett SeldonAudrey JordaanSuthananda N SunasseeDigby Francis WarnerDavid W GammonPublished in: Medicines (Basel, Switzerland) (2022)
Tuberculosis (TB) remains a public health crisis, requiring the urgent identification of new anti-mycobacterial drugs. We screened several organic and aqueous marine invertebrate extracts for their in vitro inhibitory activity against the causative organism, Mycobacterium tuberculosis . Here, we report the results obtained for 54 marine invertebrate extracts. The chemical components of two of the extracts were dereplicated, using 1 H NMR and HR-LCMS with GNPS molecular networking, and these extracts were further subjected to an activity-guided isolation process to purify the bioactive components. Hyrtios reticulatus yielded heteronemin 1 and Jaspis splendens was found to produce the bengamide class of compounds, of which bengamides P 2 and Q 3 were isolated, while a new derivative, bengamide S 5 , was putatively identified and its structure predicted, based on the similarity of its MS/MS fragmentation pattern to those of other bengamides. The isolated bioactive metabolites and semi-pure fractions exhibited M. tuberculosis growth inhibitory activity, in the range <0.24 to 62.50 µg/mL. This study establishes the bengamides as potent antitubercular compounds, with the first report of whole-cell antitubercular activity of bengamides P 2 and Q 3 .
Keyphrases
- mycobacterium tuberculosis
- public health
- ms ms
- pulmonary tuberculosis
- magnetic resonance
- stem cells
- high resolution
- single cell
- emergency department
- mass spectrometry
- hiv aids
- human immunodeficiency virus
- liquid chromatography tandem mass spectrometry
- mesenchymal stem cells
- simultaneous determination
- adverse drug
- liquid chromatography
- tandem mass spectrometry
- high performance liquid chromatography